Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference

Early Positive Phase 2 efficacy and safety data are both statistically significant and clinically meaningful. No SAE related to Silmitasertib was reported. Silmitasertib is a host-directed antiviral ...

Full "IntellAsia: Resources" article